跳至主要内容
临床试验/JPRN-UMIN000002344
JPRN-UMIN000002344已完成未知

Good combination therapy, alpha-blocker and imidafenacin, for Nocturia of Benign Prostatic Hyperplasia with OAB in Osaka-Hokuriku study group. - Good-Night study

Osaka-Hokuriku maleLUTS Conference Secretariat0 个研究点目标入组 300 人开始时间: 2009年8月17日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
300

研究概览

简要总结

Add-on anticholinaergic therapy for residual nocturia in patients with lower urinary tract symptoms receiving alpha 1- blocker treatmen: a multi-centre, prospective, randomised study. A short half-life anticholinergic is suggested to be safe and effective as an add-on therapy for residual nocturia in patients with male LUTS receiving alpha 1-blocker treatment. Anticholinergic admiistration nightly could reduce the nocturnal urine volume.

研究设计

研究类型
Interventional

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
Male

入选标准

  • 未提供

排除标准

  • 1) Urinary retention within a year 2) Residual urine >=50mL 3) Suspect of prostate cancer 4) Treatment of any anti-muscarinic agent or beta-stimulants within a month. 5) Indwelling catheter or self intermittent urinary catherization 6) Diseases that affect nocturia (sleep apnea syndrome, Restless legs syndrome, insomnia etc.) 7) The shift work and circadian rhythm disorder, patients with irregular lifestyle 8) Bladder training conducted over the past 10 days 9) Active urinary tract infection 10) Having been given hormones or 5 alpha-reductase inhibitor within the past six months 11) Contraindication to Imidafenacin (Primary angle-closure glaucoma, urinary retention, Obstructive intestinal disease, paralytic ileus, gastrointerstinal atony, myastania gravis) 12) Judged as being unsuitable for the trial by the researcher.

研究者

发起方
Osaka-Hokuriku maleLUTS Conference Secretariat

相似试验